Want to see ZIVO full AI Analyst Report?
ZIVO Stock Chart & Stats
$5.00
$0.00(0.00%)
At close: 4:00 PM EDT
$5.00
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1.11 - $19.65
Previous CloseN/A
Volume1.00
Average Volume (3M)586.00
Market Cap
$17.60M
Enterprise Value$14.92M
Total Cash (Recent Filing)$113.80K
Total Debt (Recent Filing)$569.66K
Price to Earnings (P/E)―
Beta0.92
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding3,888,595
10 Day Avg. Volume232
30 Day Avg. Volume586
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)-8.87
Price to Sales (P/S)279.23
P/FCF Ratio-10.11
Enterprise Value/Market Cap0.85
Enterprise Value/Revenue227.34
Enterprise Value/Gross Profit700.82
Enterprise Value/Ebitda-2.73
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)-1.08
Revenue Forecast (FY)$1.19M
Bulls Say, Bears Say
Bulls Say
Licensing AgreementsZIVO is engaged in constructive discussions with two major global animal health companies regarding potential licensing agreements for ZIVO’s coccidiosis product.
Poultry Health OpportunitiesPositive results from the avian flu study and plans for an additional trial are viewed favorably as it could expand ZIVO’s opportunities in poultry health.
Bears Say
Balance Sheet ConcernsThere is a risk that a deal does not come to fruition, combined with lingering concerns regarding the balance sheet and access to capital.
Capital Raising ChallengesOngoing challenges of raising capital as an unlisted security is a concern.
Cash And Debt SituationZIVO had cash and equivalents of $159K and debt of $355K, and it is expected to burn an average of $1.7M per quarter through 2025, relying on private placements or high interest-rate loans for funding.
Zivo Bioscience News
ZIVO FAQ
What was Zivo Bioscience Inc’s price range in the past 12 months?
Zivo Bioscience Inc lowest stock price was $1.10 and its highest was $19.65 in the past 12 months.
What is Zivo Bioscience Inc’s market cap?
Zivo Bioscience Inc’s market cap is $17.60M.
When is Zivo Bioscience Inc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Zivo Bioscience Inc’s earnings last quarter?
Zivo Bioscience Inc released its earnings results on Nov 13, 2023. The company reported -$1.05 earnings per share for the quarter, the consensus estimate of -$1.05 by $0.
Is Zivo Bioscience Inc overvalued?
According to Wall Street analysts Zivo Bioscience Inc’s price is currently Overvalued.
Does Zivo Bioscience Inc pay dividends?
Zivo Bioscience Inc does not currently pay dividends.
What is Zivo Bioscience Inc’s EPS estimate?
Zivo Bioscience Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Zivo Bioscience Inc have?
Zivo Bioscience Inc has 3,888,595 shares outstanding.
What happened to Zivo Bioscience Inc’s price movement after its last earnings report?
Zivo Bioscience Inc reported an EPS of -$1.05 in its last earnings report, expectations of -$1.05. Following the earnings report the stock price went down -0.112%.
Which hedge fund is a major shareholder of Zivo Bioscience Inc?
Currently, no hedge funds are holding shares in ZIVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Zivo Bioscience Inc
ZIVO Bioscience, Inc. is a research and development firm that specializes in the creation and commercialization of natural bioactive compounds. These unique ingredients, derived from its proprietary algae cultures, are licensed and sold to manufacturers producing goods for animal health, human consumption, dietary supplements, and medical foods. The company operates at the intersection of biotechnology and agricultural technology, boasting a comprehensive intellectual property portfolio. This includes distinct algal and bacterial strains, advanced biologically active molecules and complexes, innovative production and cultivation techniques, and various inventions, some patented and others pending approval, all geared towards improving human and animal well-being. Its product applications are broad, addressing areas such as promoting gut health in poultry, combating bovine mastitis, improving joint function in canines, modulating the human immune system, providing algal biomass for direct human consumption, and offering biomass-based solutions for skin care and anti-aging. Founded originally as Health Enhancement Products, Inc., the company officially rebranded to ZIVO Bioscience, Inc. in October 2014. Its corporate operations are based in Bloomfield Hills, Michigan.
Technical Analysis
Palatin Technologies
―
Citius Pharmaceuticals
―
Cyclerion Therapeutics
―
Passage Bio
―
Jasper Therapeutics
―
Ownership Overview
50.75% Insiders
0.01% Other Institutional Investors
49.24% Public Companies and
Individual Investors